Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.44)
# 300
Out of 5,241 analysts
234
Total ratings
45.5%
Success rate
29.3%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Neutral | $123 → $53 | $53.01 | -0.02% | 7 | Apr 6, 2026 | |
| ADMA ADMA Biologics | Downgrades: Neutral | n/a | $8.27 | - | 10 | Mar 26, 2026 | |
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $7.38 | +116.80% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $27.05 | -66.73% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $66.86 | +86.96% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $6.92 | +174.57% | 2 | Jan 15, 2026 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $19.65 | +144.27% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $6.69 | +258.74% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $5.09 | +273.28% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $11.01 | +117.98% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $38 | $29.01 | +30.99% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $49.43 | +27.45% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $25.00 | +320.00% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $71.47 | +65.10% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $59.27 | +24.85% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $6.92 | +131.21% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $28.79 | +4.20% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $17.55 | +361.54% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.96 | +17.45% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.94 | +2,184.26% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.24 | +2,798.55% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $31.34 | +113.78% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.17 | +307.67% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.12 | +156.41% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.46 | +347.15% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.49 | +227.87% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.81 | +1,620.75% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.93 | +1,297.70% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.25 | +1,580.00% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.25 | +380.00% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.23 | +8,668.08% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $10.36 | +122.01% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.61 | +148,537.49% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.47 | +5,682.31% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $8.59 | +1,995.46% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.66 | +10,743.37% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.39 | +691.37% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.42 | +4,125.35% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.73 | +12,187.53% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.60 | +419,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $0.53 | +571,866.13% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Apr 6, 2026
Downgrades: Neutral
Price Target: $123 → $53
Current: $53.01
Upside: -0.02%
ADMA Biologics
Mar 26, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.27
Upside: -
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $7.38
Upside: +116.80%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $27.05
Upside: -66.73%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $66.86
Upside: +86.96%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $6.92
Upside: +174.57%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $19.65
Upside: +144.27%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $6.69
Upside: +258.74%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $5.09
Upside: +273.28%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $11.01
Upside: +117.98%
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $29.01
Upside: +30.99%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.43
Upside: +27.45%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $25.00
Upside: +320.00%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $71.47
Upside: +65.10%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $59.27
Upside: +24.85%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.92
Upside: +131.21%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $28.79
Upside: +4.20%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.55
Upside: +361.54%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $5.96
Upside: +17.45%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.94
Upside: +2,184.26%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.24
Upside: +2,798.55%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $31.34
Upside: +113.78%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.17
Upside: +307.67%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.12
Upside: +156.41%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.46
Upside: +347.15%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.49
Upside: +227.87%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.81
Upside: +1,620.75%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $0.93
Upside: +1,297.70%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.25
Upside: +1,580.00%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.25
Upside: +380.00%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.23
Upside: +8,668.08%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $10.36
Upside: +122.01%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.61
Upside: +148,537.49%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.47
Upside: +5,682.31%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $8.59
Upside: +1,995.46%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.66
Upside: +10,743.37%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.39
Upside: +691.37%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.42
Upside: +4,125.35%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.73
Upside: +12,187.53%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.60
Upside: +419,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $0.53
Upside: +571,866.13%